Nomad Atomics’ Post

Did you hear about MicroQuin's project aboard the #ISS? #5 Space and Pharma Success Stories MicroQuin's microgravity experiment grows BI-1 crystals (a crucial drug target with implications for treating various diseases including #cancer), unlocking crucial insights into its structure and paving the path for #advancements in therapeutics. Here's the scoop: BI-1 has been difficult to study on Earth due to challenges in expressing and purifying it. But in the #microgravity environment of the ISS, MicroQuin has achieved something remarkable. By growing crystals of BI-1 in #microgravity, they've obtained invaluable insights into its structure. These crystals could hold the key to developing new #therapeutics that combat diseases more effectively than ever before. "We got some amazing crystals on the #ISS, which we utilised for structural analysis. BI-1 structure will increase our ability to make therapeutics to combat the world’s top diseases” says Scott Robinson, PhD, CQF, Microquin. Imagine the possibilities: targeted treatments for #cancer, #liverdiseases, #autoimmunedisorders, and more, all inspired by research conducted in space. MicroQuin's work opens doors to a future where #diseases are tackled with precision. Stay tuned for updates as they continue their journey of #discovery among the stars! Read More: https://lnkd.in/gdV6dNma #drugdiscovery #cancerresearch #microgravity #proteincrystallisation #ISS 

In a groundbreaking achievement, mesenchymal stem cells (MSC) were effectively bioprinted into a human knee meniscus aboard the International Space Station (ISS) in 2023. Led by the biomedical research division of the Uniformed Services University, this milestone emphasizes the transformative potential of space exploration in reshaping medical innovation. The pivotal contributions of Redwire's 3D BioFabrication Facility and RoosterBio Inc.'s Ready-to-Print (RTP)® cell vials, coupled with SpaceX's logistical support, were instrumental in achieving this breakthrough. Beyond propelling biomedical research forward, this achievement has promising prospects for healthcare in future space colonization endeavors.   Learn more: https://lnkd.in/d82xD27h   #MSCBioprinting #MesenchymalStemCells #Health #Healthcare #StemCells  #Research #SpaceX #Healthcare #Space

In the discussion on #AddPhotonicsOnLinkedIn, Jan Brubacher and Patricia Panchak brought up the idea that the LinkedIn industry categories might be based on #NAICS - the North American Industry Classification System, where photonics is also badly represented. I think getting #photonics on #NAICS is actually the even more important issue! DO YOU AGREE? Let's think about #AddPhotonicsToNAICS: - This will have to be done by a working group submitting an application, which needs various careful considerations on how exactly to fit photonics into that categorization scheme. - I think this is really a task for the big photonics societies, ideally a cooperation of the global societies @SPIE and @Optica, possibly also with @EPIC and @Photonics21 (although European), @IEEE Photonics Society and more. It belongs to their mission, and in contrast to me, they are paid for #advocating #photonics. - NAICS is updated only every 5 years. For the next version (2027), proposals need to be submitted in December 2024 according to @Patricia Panchak! - So the time to act is *now*, and my first question is: Is this possibly on the way already? DOES ANYONE KNOW? Meanwhile, we should keep the campaign #AddPhotonicsOnLinkedIn going - see my next posting. As always, please support the community by engaging in discussions on that, e.g. with new thoughts in reposts or comments. We can benefit hugely from a good exchange of ideas!

What an enthralling day filled with discovery! I had the privilege of visiting Geneva to delve into the fascinating world of CERN, the renowned institution probing the most fundamental particles and laws of the universe. While the origins of the Big Bang remain elusive, the researchers at CERN are steadily advancing our understanding. CERN's contributions to humanity are monumental. Thanks to their groundbreaking work, we've witnessed the birth of the World Wide Web, PET technology, touch screens, and even the first 3D color X-ray images of the human body. My focus during the visit was on #nuclear #medicine and the pivotal role of #radioisotopes, which save millions of lives annually. These isotopes are indispensable for diagnostic imaging across various health conditions and for combating #cancer through specific treatments. The concept of using radioisotopes to fight cancer isn't new; Marie Sklodowska-Curie herself advocated for radium's potential as a cure in a 1921 article for The New York Times. I owe a debt of gratitude to Thierry Stora for introducing me to CERN-Medicis, a facility dedicated to researching medical radionuclides and pioneering mass separation techniques. I also extend my thanks to Laura Lambert for generously allowing me to witness the intricate process of radioisotope production in her laboratory. From target preparation to irradiation and separation, each step was a testament to human ingenuity. Additionally, Sven de Man's insights into robotic handling techniques for maintaining safety and preventing contamination were eye-opening. Radioisotopes, whether naturally occurring or manmade, play a vital role in modern medicine. While they offer immense therapeutic potential, their short half-lives present logistical challenges in the supply chain. This underscores the importance of on-site production facilities like those at HUG - Hopital Universitaire de Genève, where accelerator expedites the delivery of molecular medicine and imaging services to patients. The field of nuclear medicine is evolving rapidly to meet growing demand. HUG's introduction of targeted radionuclide therapies to patients in 2023 is a testament to this progress, promising improved outcomes with fewer side effects. As articulated by Professor Valentina GARIBOTTO, while molecular medicine continues to advance, it's not without its challenges. Regulatory, technical, political, and financial obstacles hinder the seamless flow of radioisotopes through the supply chain. Philippe C. and I are collaborating on an European Economic and Social Committee opinion to highlight these challenges and propose solutions. Despite Europe's leading position in radioisotope production, it remains vulnerable to dependencies on third countries for essential materials and processing operations. It's imperative that EU Member States prioritize the reinforcement of Europe's capacities to ensure the security of radioisotope supplies for medical purposes.

𝗔𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗶𝗼𝗻 𝗰𝗵𝗮𝗻𝗻𝗲𝗹 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝘄𝗶𝘁𝗵 𝗹𝗶𝗽𝗶𝗱 𝗯𝗶𝗹𝗮𝘆𝗲𝗿 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 For decades, planar artificial lipid bilayers have been a reliable model for studying channel-forming pores and ion channels through voltage clamp electrophysiology. These chemically well-defined systems have led to countless breakthroughs in understanding membrane dynamics. A major innovation in this field is the Micro-Electrode Cavity Array (MECA) technology, integrated into the Orbit 16 TC and Orbit mini devices, and produced by our partner, Ionera. Unlike traditional methods, MECA technology significantly improves both the throughput and ease of use of lipid bilayer recordings by allowing parallel experiments. This advancement enables researchers to achieve higher efficiency and more accurate results, making lipid bilayer studies more accessible and scalable. Each MECA chip contains µm-sized micro-cavities, spanned by lipid bilayers and equipped with Ag/AgCl microelectrodes, ensuring high-resolution, low-noise recordings with minimal stray capacitance. Curious to learn more about the planar lipid bilayer technique? We've prepared some valuable resources for you to explore this fascinating method. 🔗 Learn more here: https://ow.ly/nglf50Tg6Tf #Electrophysiology #LipidBilayers #IonChannels #Biophysics #MEmebraneBiophysics #MECA #BLM

ViaLase Secures $40 Million in Series C Funding to Advance Novel Glaucoma Treatment Excited to announce that ViaLase, Inc has closed a $40 million Series C funding round! This funding will fuel the commercialization of our groundbreaking ViaLase® Laser, a potential first-in-class femtosecond laser for treating primary open-angle glaucoma. The ViaLase Laser utilizes a minimally invasive procedure called FLigHT (femtosecond laser image-guided high-precision trabeculotomy) to create channels in the trabecular meshwork, reducing intraocular pressure. This technology has the potential to revolutionize glaucoma treatment by offering ophthalmologists greater precision and visibility. https://lnkd.in/dHxySXvF #glaucoma #femtosecondlaser #ophthalmology #funding #medicaltechnology #FLigHT #visioncare #PhotonicSpots #PhotonicsTimes Photonics Spectra

Pangolin Scales project with Anouk Wipprecht 🥰🥰! Anouk has crafted a dress with 64 integrated actuators (32 movable scales, 32 LEDs), and g.tec has connected it to our 1024-channel BCI system, realized with g.Pangolin 🥰🥰🥰. The g.Pangolin electrodes comprise grids with 16 channels each. By situating 64 channels on the human scalp, we can record from 1024 EEG channels. Initially, EEG data from Megi was recorded to calibrate the BCI system, and then, through the dress's API, the actuators were controlled in real-time. 👉To learn more about the Pangolin Dress: https://lnkd.in/d2H2g-uc 👉To read more about the BCI system: https://lnkd.in/dP_Y4iGm 👉To learn more about g.tec: https://lnkd.in/gnZryzQQ 👉To get an offer for the setup: https://lnkd.in/dPuTcsWA #BCI #EEG #gtecmedical #neurotechnology #neuroscience #braincomputerinterface

Early birds here at #SfN2024! ☀️ We are looking forward to presenting great data with our collaborators from Axxam and Fraunhofer-Institute for Biomedical Engeneering! We have been investigating lysosomal ion channels on poster X34 and the effects of astrocytes on ion currents in neurons (when co-cultured) on poster X35. Exciting science, and fully automated too! Stop by if you are here to learn more! ]i[ ❤️ neurons (and astrocytes 😊) #automatedpatchclamp #lysosomes #ionchannels #SSMelectrophysiology #transporters #neurons #astrocytes

Retinitis pigmentosa is a rare genetic disorder that causes vision loss. Currently, there is no cure for this but can microgravity pose a solution? #4 Space & Pharma Success Stories LambdaVision, Inc. turned to the microgravity environment to manufacture artificial retinas that will restore significant vision in patients with the disorder. Led by Nicole Wagner, Ph.D., the company developed a protein-based artificial retina through a meticulous layer-by-layer manufacturing process. “To date, we’ve flown a total of eight missions to the ISS,” said Wagner. “Most of those missions have focused primarily on improving the hardware, automation, imaging capabilities, and in-orbit processes and controls.” Previous flights yielded 10 test retinas, proving the feasibility of the manufacturing process. Now, the company is aiming to make it more scalable. This effort by LambdaVision can potentially improve the quality of life for 1.5 million people on the globe suffering from Retinitis pigmentosa! Congratulations LambdaVision, Inc., You’ve got the vision!! ;) Read More: https://lnkd.in/d7e4NQJy. #microgravity #retinitispigmentosa #drugdiscovery #space #biotech #lambdavision #innovation

Spatiotemporal expression and control of haemoglobin in space Nature https://lnkd.in/gzhej5sa